MedTrace Logo

Multiparametric Assessment of Bone Response in mCRPC Patients Treated With Cabozantinib

NCT05265988 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2024-07-31

No results posted yet for this study

Summary

Multiparametric assesment of bone response in mCRPC patients treated with Cabozantinib upon progression to chemotherapy and next generation hormonal agents: a phase II study

Conditions

  • Carcinoma Prostate

Interventions

DRUG

Cabozantinib

Cabozantinib at initial dosage of 40 mg per day and continuation of androgen deprivation therapy

Sponsors & Collaborators

  • Alfredo Berruti

    lead OTHER

Principal Investigators

  • Alfredo Berruti · Asst Degli Spedali Civili Di Brescia

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-11-29
Primary Completion
2024-06-29
Completion
2024-06-29

Countries

  • Italy

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05265988 on ClinicalTrials.gov